307 related articles for article (PubMed ID: 20092407)
1. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
[TBL] [Abstract][Full Text] [Related]
2. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.
Manoff SB; Liss C; Caulfield MJ; Marchese RD; Silber J; Boslego J; Romero-Steiner S; Rajam G; Glass NE; Whitney CG; Carlone GM
J Infect Dis; 2010 Feb; 201(4):525-33. PubMed ID: 20088694
[TBL] [Abstract][Full Text] [Related]
3. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil.
Brandão AP; de Oliveira TC; de Cunto Brandileone MC; Gonçalves JE; Yara TI; Simonsen V
Vaccine; 2004 Dec; 23(6):762-8. PubMed ID: 15542200
[TBL] [Abstract][Full Text] [Related]
4. Immunological responses to pneumococcal vaccine in frail older people.
Ridda I; Macintyre CR; Lindley R; Gao Z; Sullivan JS; Yuan FF; McIntyre PB
Vaccine; 2009 Mar; 27(10):1628-36. PubMed ID: 19100304
[TBL] [Abstract][Full Text] [Related]
5. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.
Hammitt LL; Bulkow LR; Singleton RJ; Nuorti JP; Hummel KB; Miernyk KM; Zanis C; Whaley M; Romero-Steiner S; Butler JC; Rudolph K; Hennessy TW
Vaccine; 2011 Mar; 29(12):2287-95. PubMed ID: 21255685
[TBL] [Abstract][Full Text] [Related]
6. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
[TBL] [Abstract][Full Text] [Related]
10. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma.
Landgren O; Björkholm M; Konradsen HB; Söderqvist M; Nilsson B; Gustavsson A; Axdorph U; Kalin M; Grimfors G
J Intern Med; 2004 Jun; 255(6):664-73. PubMed ID: 15147530
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
12. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.
Silfverdal SA; Skerlikova H; Zanova M; Papúchová D; Traskine M; Borys D; Schuerman L
Pediatr Infect Dis J; 2011 Sep; 30(9):e155-63. PubMed ID: 21572373
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.
Grabenstein JD; Manoff SB
Vaccine; 2012 Jun; 30(30):4435-44. PubMed ID: 22542818
[TBL] [Abstract][Full Text] [Related]
15. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
Musher DM; Manoff SB; McFetridge RD; Liss CL; Marchese RD; Raab J; Rueda AM; Walker ML; Hoover PA
Hum Vaccin; 2011 Sep; 7(9):919-28. PubMed ID: 21860256
[TBL] [Abstract][Full Text] [Related]
16. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.
Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E
Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024
[TBL] [Abstract][Full Text] [Related]
17. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
[TBL] [Abstract][Full Text] [Related]
18. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial.
O'Brien KL; Moisi J; Moulton LH; Madore D; Eick A; Reid R; Weatherholtz R; Millar E; Hu D; Hackell J; Kohberger R; Siber G; Santosham M
J Infect Dis; 2007 Jul; 196(1):104-14. PubMed ID: 17538890
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
[TBL] [Abstract][Full Text] [Related]
20. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.
Ohshima N; Nagai H; Matsui H; Akashi S; Makino T; Akeda Y; Oishi K
Vaccine; 2014 Feb; 32(10):1181-6. PubMed ID: 24120483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
